company background image
SUVENPHAR logo

Suven Pharmaceuticals NSEI:SUVENPHAR Stock Report

Last Price

₹1.17k

Market Cap

₹297.4b

7D

10.3%

1Y

79.6%

Updated

17 Apr, 2025

Data

Company Financials +

Suven Pharmaceuticals Limited

NSEI:SUVENPHAR Stock Report

Market Cap: ₹297.4b

SUVENPHAR Stock Overview

Operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. More details

SUVENPHAR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 38.88% per year

Risk Analysis

No risks detected for SUVENPHAR from our risk checks.

Suven Pharmaceuticals Limited Competitors

Laurus Labs

NSEI:LAURUSLABS

₹338.7b

Pfizer

NSEI:PFIZER

₹190.5b

Ajanta Pharma

NSEI:AJANTPHARM

₹336.5b

Ipca Laboratories

NSEI:IPCALAB

₹356.3b

Price History & Performance

Summary of share price highs, lows and changes for Suven Pharmaceuticals
Historical stock prices
Current Share Price₹1,168.10
52 Week High₹1,360.00
52 Week Low₹598.00
Beta1.34
1 Month Change3.03%
3 Month Change8.21%
1 Year Change79.60%
3 Year Change103.47%
5 Year Change712.31%
Change since IPO593.13%

Recent News & Updates

author-image

Converting Increased RFPs Into Contracts Will Strengthen Future Prospects

Feb 23 Strategic acquisitions and diversification into niche markets enhance Suven's revenue potential and improve margins through high-value offerings.

Recent updates

author-image

Converting Increased RFPs Into Contracts Will Strengthen Future Prospects

Feb 23 Strategic acquisitions and diversification into niche markets enhance Suven's revenue potential and improve margins through high-value offerings.

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07
Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03
Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04
Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13
With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08
Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Shareholder Returns

SUVENPHARIN PharmaceuticalsIN Market
7D10.3%5.1%5.3%
1Y79.6%12.9%2.1%

Return vs Industry: SUVENPHAR exceeded the Indian Pharmaceuticals industry which returned 12.9% over the past year.

Return vs Market: SUVENPHAR exceeded the Indian Market which returned 2.1% over the past year.

Price Volatility

Is SUVENPHAR's price volatile compared to industry and market?
SUVENPHAR volatility
SUVENPHAR Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement7.5%
Market Average Movement7.3%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.9%

Stable Share Price: SUVENPHAR has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: SUVENPHAR's weekly volatility (7%) has been stable over the past year.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

SUVENPHAR logo
Suven Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts

New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides

Key Takeaways Strategic acquisitions and entry into high-growth segments enhance revenue and margins by tapping into high-value markets like oligonucleotides and ADCs. Diversification and expansion into specialty segments with differentiated technology and M&A bolster competitive advantage and drive predictable, accelerated growth. Strategic acquisition reliance and volatile demand may strain cash flow, impacting financial stability, margins, and long-term earnings if expected synergies aren't realized.
View narrative
₹1.40k
FV
16.4% undervalued intrinsic discount
65.46%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
1 day ago author updated this narrative
View Suven Pharmaceuticals Community

About the Company

FoundedEmployeesCEOWebsite
1989n/aSudhir Singhsuvenpharm.com

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India.

Suven Pharmaceuticals Limited Fundamentals Summary

How do Suven Pharmaceuticals's earnings and revenue compare to its market cap?
SUVENPHAR fundamental statistics
Market cap₹297.36b
Earnings (TTM)₹2.79b
Revenue (TTM)₹10.48b

106.5x

P/E Ratio

28.4x

P/S Ratio

Is SUVENPHAR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SUVENPHAR income statement (TTM)
Revenue₹10.48b
Cost of Revenue₹3.90b
Gross Profit₹6.58b
Other Expenses₹3.79b
Earnings₹2.79b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 28, 2025

Earnings per share (EPS)10.97
Gross Margin62.78%
Net Profit Margin26.63%
Debt/Equity Ratio1.9%

How did SUVENPHAR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/17 03:25
End of Day Share Price 2025/04/17 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Suven Pharmaceuticals Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vijayaraghavan SwaminathanAvendus Spark
Harith AhamedAvendus Spark
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.